BUWA Stock Overview
Manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 3/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for BUWA from our risk checks.
Bio-Rad Laboratories, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$309.80 |
| 52 Week High | US$351.80 |
| 52 Week Low | US$244.70 |
| Beta | 0.94 |
| 11 Month Change | -0.26% |
| 3 Month Change | 11.48% |
| 1 Year Change | 9.47% |
| 33 Year Change | -51.97% |
| 5 Year Change | -7.25% |
| Change since IPO | 1,324.37% |
Recent News & Updates
Recent updates
Shareholder Returns
| BUWA | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -5.8% | -6.1% | -1.3% |
| 1Y | 9.5% | 2.0% | 7.4% |
Return vs Industry: BUWA exceeded the German Life Sciences industry which returned 2% over the past year.
Return vs Market: BUWA exceeded the German Market which returned 7.4% over the past year.
Price Volatility
| BUWA volatility | |
|---|---|
| BUWA Average Weekly Movement | 4.8% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: BUWA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: BUWA's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1952 | 8,030 | Norman Schwartz | www.bio-rad.com |
Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.
Bio-Rad Laboratories, Inc. Fundamentals Summary
| BUWA fundamental statistics | |
|---|---|
| Market cap | €8.80b |
| Earnings (TTM) | -€747.78m |
| Revenue (TTM) | €2.48b |
3.6x
P/S Ratio-12.0x
P/E RatioIs BUWA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BUWA income statement (TTM) | |
|---|---|
| Revenue | US$2.58b |
| Cost of Revenue | US$1.17b |
| Gross Profit | US$1.41b |
| Other Expenses | US$2.19b |
| Earnings | -US$778.69m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -27.81 |
| Gross Margin | 54.54% |
| Net Profit Margin | -30.18% |
| Debt/Equity Ratio | 15.9% |
How did BUWA perform over the long term?
See historical performance and comparison